Abdominal Obesity Metabolic Syndrome
Conditions
Brief summary
A growing body of evidence demonstrates that increased adipose mass, especially visceral adipose tissue, contributes directly towards an increase in systemic inflammation, (micro-)vascular dysfunction and the burden of cardiovascular disease (CVD), insulin resistance and type 2 diabetes. Advanced glycation/lipoxidation endproducts (AGEs/ALEs) are a heterogeneous family of unavoidable by-products, which are formed by reactive metabolic intermediates derived from glucose and lipid oxidation. In addition to the overwhelming amount of data demonstrating the role of AGEs/ALEs in the development of (micro-)vascular dysfunction and disease, accumulation of AGEs/ALEs in the expanding adipose tissue contributes to the dysregulation of adipokines and the development of insulin resistance. The investigators want to examine, in a double-blind randomized placebo controlled parallel study, the physiological effect of a dietary intervention with pyridoxamine in abdominally obese persons. A sub-study is implemented next to the clinical trial. The objective of the sub-study is to measure the metabolization and kinetics of pyridoxamine in plasma and urine with UPLC-MS/MS. The sub-study comprises of 5 additional healthy volunteers, with pyridoxamine as an oral supplement.
Interventions
DIETARY_SUPPLEMENTPyridoxamine
DIETARY_SUPPLEMENTPlacebo
Sponsors
Top Institute Food and Nutrition
Center for Translational Molecular Medicine
Maastricht University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Abdominal obesity: Waist circumference for men should be above 102 cm and for women above 88 cm. * Caucasian (because of skin fluorescence and capillary microscopy measurements) * Aged 18-75 years
Exclusion criteria
* Diabetes (i.e. using anti-diabetic medication, fasting glucose \>7.0 mmol/L, HbA1c \>6.5%). * Active or history of cardiovascular disease (e.g. stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death) * Hyperlipidemia (defined as serum total cholesterol \> 8 mmol/L or TG \> 4 mmol/L) * Smoking (\>10 cigarettes per day) * High alcohol usage (\>4 U/day) or drug abuse * Use of medication known to influence glucose metabolism, vascular function (e.g. glucocorticosteroids, NSAID's) * Higher grade hypertension (\> 179 mmHg SBP and/or \> 109 mmHg DBP) in order not to expose subjects to unnecessary risks) * Known allergic reaction to ultrasound contrast-agent * Pulmonary or inflammatory disease * Kidney failure or electrolyte disorders * Use of dietary supplements or an investigational product within the previous month * Unstable body weight (no drastic changes in life style before or during the intervention are allowed, this means no weight gain or loss \>3 kg in the last two months) * Pregnancy or lactation * No change in use of oral anticonceptiva or IUD (12 weeks prior of during the intervention) * Unwillingness to give up being a blood donor (or having donated blood) from 8 weeks prior to the start of the study and during the study * Insufficient knowledge of the Dutch language
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Insulin sensitivity | Difference after 8 weeks of intervention | Assessed by hyperinsulinemic-euglycemic clamp |
| Microvascular function | Difference after 8 weeks of intervention | Assessed by contrast-enhanced ultrasound (CEUS) in skeletal muscle |
Countries
Netherlands
Outcome results
None listed